Answers are grounded in this paper and cite their sources.
Phenobarbital (PB) is widely used for long-term management of canine epilepsy, but treatment may alter hepatic biochemical variables and, less commonly, cause idiosyncratic hematological reactions. This retrospective observational repeated-measure study evaluated associations between serum PB concentration and concurrent hepatic and hematological findings and explored their predictive value. The dataset comprised 233 laboratory visits from 67 dogs. Repeated-measures generalized estimating equations, within-dog and longitudinal analyses, receiver operating characteristic analyses, and dog-grouped machine-learning models were applied. Serum PB concentration showed its clearest association with alkaline phosphatase (ALP). Each 10 μg/mL increase in PB was associated with a 37.6% increase in ALP activity (95% confidence interval [CI], 11.6–69.7%; p = 0.0028); after adjustment for age, sex, neutering status, and diagnostic category, the increase was 34.9% (95% CI, 10.2–65.0%; p = 0.0036) and remained significant after false-discovery-rate correction. No comparable concentration-dependent relationship was identified for the principal hematological outcomes. A PB concentration > 30 μg/mL was relatively specific but poorly sensitive for hepatic biochemical abnormalities, and machine-learning models showed only modest or poor discrimination. Serum PB concentration should therefore be interpreted together with serial biochemical and hematological measurements rather than as a stand-alone indicator of treatment safety.
No takes yet. Share an insight, caveat, or question.
Ginoudis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: